HC Wainwright Issues Optimistic Forecast for Nkarta Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Nkarta in a research note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($1.84) per share for the year, up from their previous forecast of ($1.86). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Nkarta’s FY2027 earnings at ($1.27) EPS, FY2028 earnings at ($0.86) EPS, FY2029 earnings at ($0.74) EPS and FY2030 earnings at ($0.60) EPS.

Nkarta (NASDAQ:NKTX) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05).

NKTX has been the subject of several other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research note on Monday, September 21st. Wall Street Zen lowered shares of Nkarta from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Stifel Nicolaus decreased their price objective on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Nkarta in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Nkarta has a consensus rating of “Moderate Buy” and an average price target of $11.20.

Nkarta Price Performance

Shares of NKTX stock opened at $1.59 on Tuesday. The company has a market capitalization of $113.88 million, a PE ratio of -0.92 and a beta of 1.24. The firm’s 50-day moving average is $2.32 and its two-hundred day moving average is $2.51. Nkarta has a 12 month low of $1.13 and a 12 month high of $3.72.

Institutional Investors Weigh In On Nkarta

Institutional investors and hedge funds have recently made changes to their positions in the stock. StoneX Group Inc. acquired a new position in shares of Nkarta in the 3rd quarter worth approximately $53,000. Samalin Investment Counsel LLC increased its holdings in Nkarta by 68.5% in the 3rd quarter. Samalin Investment Counsel LLC now owns 68,658 shares of the company’s stock valued at $180,000 after purchasing an additional 27,908 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in Nkarta in the 2nd quarter valued at approximately $45,000. Spark Investment Management LLC acquired a new stake in Nkarta in the 2nd quarter valued at approximately $33,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Nkarta in the 2nd quarter valued at approximately $30,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

Key Nkarta News

Here are the key news stories impacting Nkarta this week:

• Positive Sentiment: Nkarta reported initial clinical responses and safety findings for NKX019 in trials for myositis and systemic sclerosis. Early data may support the therapy’s potential, though the results are preliminary. Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
• Positive Sentiment: HC Wainwright raised its earnings-per-share estimates for 2027–2030, projecting smaller losses than previously expected, and maintained its Buy rating. Its 2026 estimate improved only slightly. Nkarta discusses initial NKX019 clinical data
• Positive Sentiment: Needham reaffirmed its Buy rating, adding to the supportive analyst commentary. Needham rating information

About Nkarta

Nkarta, Inc is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s platform is designed to produce allogeneic, or donor-derived, NK cells that can be engineered with chimeric antigen receptors (CARs) to recognize and attack targeted cells.

Nkarta’s research and development programs have included NKX019, a CD19-targeted CAR NK-cell therapy investigated for B-cell malignancies and autoimmune disorders, and NKX101, an NKG2D-targeted CAR NK-cell therapy developed for certain solid tumors.